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CD4-independent association between HIV-1 gp120 and CXCR4:
functional chemokine receptors are expressed in human neurons
Joseph Hesselgesser*, Meredith Halks-Miller*, Virginia DelVecchio*, Stephen C.
Peiper†, James Hoxie‡, Dennis L. Kolson‡, Dennis Taub# and Richard Horuk*
Background: Chemokines are a family of proteins that chemoattract and activate
immune cells by interacting with specific receptors on the surface of their
targets. We have shown previously that chemokine receptors including the
interleukin-8 receptor B (CXCR2) and the Duffy blood group antigen are
expressed on subsets of neurons in various regions of the adult central nervous
system.
Results: Using a combination of immunohistochemical staining and receptor-
binding studies, we show that hNT cells, which are differentiated human
neurons derived from the cell line NTera 2, express functional chemokine
receptors of the C–X–C and C–C types. These chemokine receptors include
CXCR2, CXCR4, CCR1 and CCR5. We demonstrate high-affinity binding of
both types of chemokines to hNT neurons and dose-dependent chemotactic
responses to these chemokines in differentiated, but not undifferentiated, NTera
2 cells. In addition, we show that the envelope glycoprotein from the T-cell-
tropic human immunodeficiency virus 1 (HIV-1) strain IIIB is a CD4-independent,
dose-dependent inhibitor of the binding of stromal cell-derived factor 1 to its
receptor, CXCR4.
Conclusions: These data support the recent findings that members of the
chemokine receptor family, including CCR5 and LESTR/Fusin (CXCR4),
function as coreceptors in combination with CD4 for HIV-1 invasion. This is the
first report of functional expression of chemokine receptors on human neurons.
Furthermore, our studies provide evidence for the direct, CD4-independent
association of the viral envelope protein of the HIV-1 strain IIIB with the
chemokine receptor CXCR4.
Introduction
Chemokines are a family of proteins that chemoattract and
activate immune cells both in vivo and in vitro [1]. They
are classified into three major families depending on
whether they have an intervening amino acid separating
the first two of their four conserved cysteine residues
(C–X–C), do not have the intervening residue (C–C) or
fail to express one of the amino-terminal cysteines (C).
The members of the C–X–C class include interleukin-8
(IL-8) and melanoma growth stimulatory activity (MGSA),
while the C–C class includes RANTES, monocyte chemo-
tactic protein-1 (MCP-1) and the macrophage inflamma-
tory proteins (MIP-1a and MIP-1b). At present, the only
C class member  is lymphotactin.
The chemokines produce their biological effects by inter-
acting with specific receptors on the surface of their target
cells [2]. So far, ten different chemokine receptors have
been cloned [3]. These receptors are characterized by a
heptahelical structure and belong to a superfamily of
serpentine receptors. Most, but not all, are coupled to
guanine nucleotide binding proteins (G proteins).
Following the finding that specific C–C and C–X–C
chemokines can inhibit human immunodeficiency virus 1
(HIV-1) infection [4–6], members of the chemokine recep-
tor family were shown to function as coreceptors in combi-
nation with the cell-surface marker CD4 for HIV-1 invasion
[7–11]. Different strains of HIV-1 appear to use different
chemokine receptors for viral fusion: macrophage-tropic
strains of HIV-1 use mainly CCR5 [8] and to a more limited
degree CCR3 and CCR2b [9–11], whereas the T-cell-tropic
strains of HIV-1 use CXCR4 [7]. 
HIV infection within the brain may result in a syndrome of
profound cognitive, behavioral, and motor impairment
termed the AIDS dementia complex (ADC) or HIV-associ-
ated dementia complex (HADC) [12], which occurs in both
adult and pediatric AIDS patients. In general, ADC is more
common and more severe as the length of HIV infection
increases, and is often more severe in children, suggesting
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that the developing central nervous system (CNS) is highly
vulnerable to HIV-1 [13,14].
Expression of C–X–C chemokine receptors within the
CNS could be important in the pathogenesis of HIV-1
infection in the CNS. We have shown previously that the
chemokine receptors CXCR2 and DARC (the Duffy
blood group antigen) are expressed on subsets of neurons
in various regions of the CNS [15]. This intriguing
finding raises several interesting questions. First, are
these receptors biologically functional? Second, is there
any evidence to suggest that other members of this family
of receptors are expressed on CNS neurons and, if so, can
any of them function as coreceptors for HIV-1 and func-
tion in ADC? Finally, does the expression of chemokine
receptors differ between cells of the immature and
mature CNS, suggesting a role for the receptors in neu-
ronal development?
To address the question of chemokine receptor function
in CNS neurons, we examined the expression of
chemokine receptors in cultured human neurons derived
from fetal brains and in terminally differentiated hNT
cells, which serve as a model for developing human CNS
neurons [16,17]. The hNT neurons are derived from an
undifferentiated cell line, NTera 2, after prolonged treat-
ment with retinoic acid. This can yield pure cultures of
cells displaying a post-mitotic neuronal phenotype with
features of immature human CNS neurons. These fea-
tures include expression of a number of neuronal proteins
including neurofilament proteins, functional glutamate
receptors and the enzyme acetylcholinesterase [18–20].
In this study, we demonstrate specific chemokine binding
to hNT cells, HIV-1 envelope protein competition for
chemokine binding, and chemotactic responses that indi-
cate expression of the biologically active chemokine
receptors CXCR2, CXCR4, CCR1 and CCR5 in hNT
neurons. We also observed CXCR2 expression in cultured
neurons from human fetal brains. These observations
suggest that there may be functional chemokine receptors
on CNS neurons within the developing nervous system
and raise intriguing questions concerning the potential
role of chemokines in normal neuronal development, neu-
ronal cell function, and the pathogenesis of neurological
dysfunction in ADC.
Results
Peptide antibodies directed against CCR1 and CCR5
Antibodies to several of the chemokine receptors that we
wished to examine were already available (see Materials
and methods), but we lacked antibodies to CCR1 and
CCR5. We therefore raised antibodies to these proteins
and tested the purified anti-CCR1 and anti-CCR5 polyva-
lent antisera by indirect immunofluorescence followed by
flow cytometry of transfectants expressing the appropriate
receptors. As shown in Figure 1, the polyvalent anti-recep-
tor antibodies (anti-CCR1 and anti-CCR5) bound to the
native receptor expressed by these transfectants. This
binding was inhibited by the presence of the appropriate
amino-terminal peptides. As assessed by fluorescence-
activated cell sorting (FACS) analysis, neither the polyva-
lent antibody nor the pre-immune serum bound to
untransfected cells or to cells expressing CXCR1, CXCR2
or DARC (data not shown). The antibodies were not,
however, tested for crossreactivity with CCR2, CCR3 and
CCR4. The reactivity of the pre-immune serum with the
receptor transfectants was equivalent to the autofluores-
cence exhibited by the cells (Fig. 1b). 
Immunological detection of chemokine receptors in hNT cells
To test for chemokine receptor expression, precursor
NTera 2 cells and differentiated hNT neurons were
stained immunohistochemically using antibodies to
CXCR2, CXCR4, CCR1, CCR5 and DARC. The hNT
cells were plated in four- and eight-well chamber slides
and stained as described in Materials and methods. Little
specific staining of the precursor NTera 2 cells was
observed (data not shown). In contrast, the differentiated
hNT neurons showed specific staining with all of the
receptor antibodies tested (Fig. 2a–f), except those against
DARC (data not shown). For the positive cells, both cell
bodies and some cellular processes were stained. As can
be seen in Figure 2, the undifferentiated NTera 2 cells
formed a background of lightly stained cells on which the
strongly reactive hNT neurons were superimposed. The
perinuclear cytoplasmic staining suggests the presence of
intracellular chemokine receptors that have not yet been
translocated to the cell surface. The specificity of the
chemokine receptor staining was established by demon-
strating either that peptides specific for the antibodies
(CXCR2 and CCR5) could appropriately block antibody
staining (Fig. 2d,f) or that specific staining was not
observed with irrelevant monoclonal and polyclonal anti-
bodies (data not shown). The neuronal hNT cells have
been reported to be CD4-negative by immunofluores-
cence and northern blot [21], and this was confirmed by
the lack of staining with CD4-specific antibodies (Fig. 2g).
The neuronal-like nature of the hNT cells was confirmed
by demonstrating positive staining with antibodies to neu-
ronal cell adhesion molecule (NCAM) and to neurofila-
ment (Fig. 2h). The astrocyte-specific marker glial
fibrillary acidic protein (GFAP) was never revealed by
immunostaining (Fig. 2i). The exact distribution of these
chemokine receptors on the hNT cells could not be deter-
mined by immunohistochemistry because the cells grow
in small, tightly packed groups (100–200 mm in diameter)
that are difficult to resolve optically. Confocal microscopy
showed that there was receptor staining in small clusters
scattered over the cell bodies and proximal processes of
the hNT cells, in addition to the intracellular perinuclear
staining (data not shown). 
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Immunological detection of chemokine receptors in human
fetal neurons
Earlier work from our laboratory showed that cultures of
human neocortex neurons derived from E17 to E22
fetuses are very similar, morphologically, to hNT cells.
Initially, having only antibodies to CXCR2 and DARC,
we used these antibodies to examine chemokine recep-
tor expression in these cells. Immunohistochemical
staining of human fetal neurons demonstrated significant
staining of neuronal fibers with a pan neurofilament anti-
body (Fig. 3a). Staining with antibodies to CXCR2
revealed a strongly staining cluster of small primitive
neurons (Fig. 3b). Astroglial cells adjacent to a cluster of
non-staining neurons stained strongly with antibodies to
GFAP (Fig. 3c). Figure 3d shows a group of neurons that
show cytoplasmic staining and staining on their processes
with antibodies to CXCR2. A large glial cell in the same
field of view shows a slight blush of staining with the
same antibody. The Fy6 antibody, specific for DARC,
did not stain these cells (data not shown). Irrelevant
polyclonal or monoclonal antibodies also failed to stain
these cells (Fig. 3e).
Chemokine receptors in hNT cells bind ligand with high
affinity
Given that we have demonstrated the presence of
chemokine receptors on hNT neurons, and that these
receptors are known to bind and respond to specific ligands
[2], we wished to determine if these cells can bind 125I-
labeled chemokines and whether this binding can be dis-
placed by an excess of unlabeled ligands. The chemokine
receptor CXCR2 binds both IL-8 and MGSA with high
affinity [22], and so we carried out receptor-binding studies
with radiolabeled IL-8. Scatchard analysis of competition
binding studies with 125I-labeled IL-8 revealed the pres-
ence of a single class of high-affinity binding sites with a
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Figure 1
Flow cytometric analysis of transfected cells with polyvalent antisera to
CCR1 and CCR5 amino-terminal peptides. (a) Binding of CCR1 antisera
to CCR1 receptor transfectants. Green line, anti-CCR1 antibody plus
FITC goat anti-rabbit IgG; red line, FITC goat anti-rabbit IgG only. (b)
Binding of CCR5 antisera to CCR5 receptor transfectants. Green line,
anti-CCR5 antibody plus FITC goat anti-rabbit IgG; purple line, anti-
CCR5 antibody, FITC goat anti-rabbit IgG and amino-terminal CCR5
peptide; red line, pre-immune serum plus FITC goat anti-rabbit IgG. 
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Figure 2
Immunohistochemical staining of hNT cells. For details of
immunohistochemistry see Materials and methods. hNT cells were
stained with antibodies to (a) CXCR4, (b) CCR1, (c) CXCR2, (d)
CXCR2 in the presence of peptides specific for the antibody, (e) CCR5,
(f) CCR5 in the presence of peptides specific for the antibody, (g) CD4,
(h) neurofilament and (i) GFAP. Bars in panels (a,b,e–g,i) equal 50mm.
Bars in panels (c,d,h) equal 100mm. 
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receptor density of 4000 sites per cell and a KD of
3.8 ± 0.4 nM (Fig. 4a). To test for binding to CXCR4, we
used stromal cell-derived factor 1 (SDF-1), which was iden-
tified recently as a ligand for CXCR4 [6,21] and found to
block the invasion of T-cell-tropic strains of HIV-1, which
use CXCR4 as a cofactor [5,6]. To probe CXCR4 binding
sites on hNT cells, we chemically synthesized and radiola-
beled SDF-1, and performed receptor-binding studies.
Scatchard analysis of competition binding studies with 125I-
labeled SDF-1 revealed a single class of high-affinity
binding sites with a receptor density of 8000 sites per cell
and a KD of 54 ± 8.3 nM (Fig. 4b). Finally, radiolabeled
MIP-1b, a high affinity ligand for CCR5 [23], was used to
characterize this receptor on hNT cells. Scatchard analysis
of competition binding studies with 125I-labeled MIP-1b
revealed a single class of high affinity binding sites with a
receptor density of 3000 sites per cell and a KD of
9.7 ± 1.6 nM (Fig. 4c). In contrast, no chemokine binding
was observed in the undifferentiated NTera 2 cells with
Figure 3
Immunohistochemical staining of human fetal neurons. For details of
staining see Materials and methods. (a) The fibers of a cluster of
primitive neurons stained strongly with a pan neurofilament antibody.
(b) Uniform staining of a cluster of primitive neurons was seen with
antibodies to CXCR2. (c) Astroglial cell stained strongly with an
antibody to glial fibrillary acidic protein in a field of non-staining
neurons (neurons indicated by arrows). (d) Antibodies to CXCR2
stained primitive neurons on processes and in the cytoplasm. A large
glial cell in the same field of view shows a slight blush of staining. (e) A
cluster of neurons stained with an irrelevant monoclonal antibody.
Figure 4
Displacement of radiolabeled chemokine binding to hNT cells. Cells
were incubated for 30 min at room temperature with radiolabeled
chemokines in the presence and absence of increasing concentrations
of unlabeled ligands. The insets show the Scatchard analysis of the
displacement binding data. (a) 125I-labeled IL-8 displaced by MGSA,
KD = 3.8 ± 0.4 nM. (b) 125I-labeled SDF-1 displaced with SDF-1,
KD = 54 ± 8.3 nM. (c) 125I-labeled MIP-1b displaced with MIP-1a,
KD = 9.7 ± 1.6 nM. Each panel shows the results from one of three
experiments performed under each condition.
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any chemokine tested (data not shown). 
Dose-dependent induction of chemotaxis in hNT neurons
The studies above strongly support the idea that high-
affinity chemokine receptors are present on the cell
surface of hNT neurons. To determine if these receptors
are functionally active, we carried out chemotaxis assays.
Chemotaxis of both precursor NTera 2 and neuronal hNT
cells were carried out as described in Materials and
methods. The hNT neurons demonstrated a potent
chemotactic response with increasing concentrations of
chemokines. A five-fold to nine-fold increase in chemo-
taxis was seen, depending on the particular chemokine
(Fig. 5a,c). All of the chemokines tested, apart from
platelet factor 4 (PF-4), which was negative, gave a typical
bell-shaped curve at concentrations up to 1 mg ml–1 (Fig.
5a,c). Based on these data, chemokine receptors on hNT
neurons are biologically functional and can elicit a cellular
response to their appropriate ligands. In contrast, as shown
in Figure 5b, the precursor cells responded poorly to
increasing concentrations of chemokines and demonstrated
at best only a two-fold increase in migratory response. 
Strain IIIB gp120 envelope protein competes with SDF-1
for binding to CXCR4
As it has been shown that hNT neurons support CD4-
independent infection with T-cell-tropic virus [21] and
that T-cell-tropic strains of HIV-1 use CXCR4 as a co-
receptor for viral fusion [7], we next examined whether
the gp120 envelope protein from the T-cell-tropic virus
strain IIIB could block SDF-1 binding to CXCR4. Com-
petition binding studies in which hNT cells were incu-
bated with 125I-labeled SDF-1 in the presence and
absence of increasing concentrations of IIIB envelope
protein demonstrated that increasing concentrations of the
envelope protein could effectively displace the radiola-
beled SDF-1 (Fig. 6a). Scatchard analysis of the competi-
tion binding studies revealed a single class of high affinity
binding sites with a receptor density of 6100 sites per cell
and a KD of 70 ± 26 nM (Fig. 6a inset). These data are
similar to those obtained when unlabeled SDF-1 was used
as the competitor (Fig. 4b). As the kinetics and dose-
response profiles of displacement for gp120 and SDF-1
were very similar (Figs 4b and 6a), it is very likely that
these molecules are binding to the same receptor on the
hNT cells. To investigate this further, 125I-labeled IIIB
gp120 was added to hNT cells and the ability of increasing
concentrations of unlabeled SDF-1 to displace the labeled
viral protein was assessed. Figure 6b shows the data from a
representative series of experiments, which demonstrated
Figure 5
The C–C chemokines MIP-1a, MIP-1b, RANTES and MCP-1 and the
C–X–C chemokines IL-8, MGSA and SDF-1 induce hNT cell migration
on laminin-coated filters. (a,c) hNT neurons and (b) undifferentiated
NT2 cells were tested for their ability to migrate in response to various
concentrations of chemokines on polycarbonate filters coated with
laminin as described in Materials and methods. After 4 h of incubation
filters were scraped, washed, stained and counted manually or by an
image analyzer. The results are expressed as the number of cells in five
high-power fields (± SE).
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that increasing concentrations of unlabeled SDF-1 dis-
placed the 125I-labeled IIIB gp120. Scatchard analysis of
the competition binding studies revealed a single class of
high-affinity binding sites with a receptor density of 9600
sites per cell and a KD of 86 ± 19 nM (Fig. 6b). These data
were similar to those observed when unlabeled gp120 was
used in competition with radiolabeled SDF-1 (Fig. 6a),
demonstrating that the two proteins are competing for
binding to one receptor, CXCR4. Radiolabeled binding of
IIIB gp120 to these cells was not inhibited by 1 mM MIP-
1a or IL-8, and there was no displaceable binding of IIIB
gp120, SDF-1, MIP-1a, MIP-1b, IL-8, MGSA or
RANTES to the undifferentiated cells (data not shown).
To further establish the specificity of SDF-1 and IIIB
gp120 binding to CXCR4, we tested whether an irrelevant
viral glycoprotein from herpes simplex virus-1 (gD HSV-1)
and a specific monoclonal antibody (12G5) to CXCR4 could
block specific binding. As shown in Figure 7, the gD HSV-1
protein had no effect on either SDF-1 or IIIB gp120
binding to CXCR4. In addition, envelope protein from the
HIV-1 T-cell-tropic viral strain BRU inhibited SDF-1
binding to CXCR4. The monoclonal antibody for CXCR4
inhibited both SDF-1 and IIIB gp120 binding in hNT cells
(Fig. 7). It has been suggested previously that galactosylce-
ramide (GalCer) can act as a CD4-independent receptor for
HIV-1 [24], but we were unable to show any effect on either
SDF-1 or IIIB binding using a specific antibody to GalCer. 
Discussion
Two separate reports recently showed that the orphan
receptor LESTR (leukocyte-expressed seven-transmem-
brane-domain receptor; [25,26]) responded to SDF-1 in
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Figure 7
Displacement of (a) 125I-labeled SDF-1 and (b) 125I-labeled IIIB gp120
from hNT cells by an irrelevant viral glycoprotein gD HSV-1 and a
specific monoclonal antibody (12G5) to CXCR4. The concentration of
radiolabeled ligand was 500 pM, and the displacing reagents were at
the following concentrations: SDF-1 and IIIB gp120, 1 mM; BRU
gp120, 330 nM; HSV-1 gD, 1 mM; anti-CXCR4 antibody, 500 nM; and
anti-GalCer antibody, 300 nM. 
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Figure 6
Radiolabeled SDF-1 and IIIB gp120 binding to hNT cells can be
displaced by their counter-ligands. Cells were incubated for 30 min at
room temperature with radiolabeled SDF-1 or IIIB gp120 in the
presence and absence of increasing concentrations of unlabeled
protein. (a) 125I-labeled SDF-1 is displaced by unlabeled IIIB gp120.
The inset shows the Scatchard analysis of the displacement binding
data, KD = 70 ± 26 nM. (b) 125I-labeled IIIB gp120 is displaced by
unlabeled SDF-1. The inset shows the Scatchard analysis of the
displacement binding data, KD = 86 ± 19 nM. Each panel shows the
results from one of three experiments performed under each condition.
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Ca2+-flux assays [5,6], and so this receptor was designated
CXCR4. Here, we demonstrate that hNT neurons express
CXCR4 and other chemokine receptors, including
CXCR2, CCR1 and CCR5, and that these receptors bind
their appropriate ligands with high affinity (Fig. 2–4).
This study is the first to report high-affinity binding of
SDF-1 to CXCR4 (Fig. 4). In addition, we show that
SDF-1 is able to stimulate chemotaxis of hNT cells, that
the magnitude of this stimulation depends on SDF-1
dose, and that half-maximal stimulation occurs with 50 nM
ligand (Fig. 5c) — which is consistent with the reported
concentration range for SDF-1-mediated induction of cell
migration and actin polymerization in T cells [27]. All of
the chemokines that demonstrate high-affinity binding to
hNT cells (Fig. 4) are able to stimulate chemotaxis in
hNT cells at half-maximal doses consistent with their
binding affinities (Fig. 5). Finally, we show that the gp120
envelope protein from a T-cell-tropic virus can inhibit
SDF-1 binding to the chemokine receptor CXCR4  in the
absence of CD4 (Figs 6,7). 
Recently, we demonstrated expression of the chemokine
receptors CXCR2 and DARC by subsets of neurons and
their processes in normal adult human brain [15]. We also
showed that CXCR2 was overexpressed in the neuritic
portion of Alzheimer’s plaques. Based on these data, we
postulated that chemokine receptors may function in
injury, maintenance or repair in the CNS. It is clear that
chemokines are important in inflammation outside the
CNS [1], but the significance of their expression in the
CNS is unclear. A number of chemokines, including MIP-
1a, MCP-1, IP-10 and RANTES, have been implicated in
inflammation in the CNS [28,29]. The distribution and
morphology of MIP-1a-immunoreactive cells were identi-
cal with those of activated astrocytes. These data suggest
that MIP-1a may be important in promoting inflammatory
and/or repair processes in the brain, possibly by attracting
or modulating inflammatory cells. Consistent with this
notion, recent studies from Karpus et al. [30] provide
strong evidence in support of the concept that this
chemokine is a major mediator in the pathogenesis of mul-
tiple sclerosis (MS). In this study, antibodies to MIP-1a
prevented the development of both acute and relapsing
paralytic disease in an experimental autoimmune
encephalomyelitis (EAE) model of MS in the mouse.
Treatment with antibody was also able to ameliorate the
severity of ongoing clinical disease. 
In addition to the induction of inflammation by
chemokines in the CNS, there is also direct experimental
evidence supporting the idea that chemokines can modu-
late normal homeostatic mechanisms in the CNS. The idea
that IL-8 functions in the CNS comes from the in situ
hybridization of a human IL-8 probe to cells in several
regions of the rat brain including the hippocampus and
cerebellum [31]. The enhanced survival of rat hippocampal
neurons induced by IL-8 in culture assays in vitro [32]
offers additional evidence that IL-8 is involved in mainte-
nance of neurons.
Based on our findings that the differentiated NTera 2
cells express the chemokine receptor CXCR4, a recently
identified coreceptor for viral fusion [7], and the report
demonstrating that these cells can be infected by the T-
cell-tropic HIV-1 strain IIIB [21], we asked whether we
could demonstrate a direct interaction between viral
gp120 and CXCR4, in the absence of CD4. The competi-
tive displacement of the CXCR4 radiolabeled ligand
SDF-1 by IIIB gp120 protein from two T-cell-tropic
strains of HIV-1, and the counter-displacement of radiola-
beled IIIB gp120 by SDF-1 is strong evidence for a direct
association between the viral glycoprotein and the
chemokine receptor CXCR4. Furthermore, this interac-
tion appears to be CD4-independent, consistent with
recent findings showing CD4-independent invasion for
some strains of HIV-2 [33]. Based on these data, it remains
a distinct possibility that the viral infection of differenti-
ated NTera 2 cells could occur via an interaction with the
chemokine receptor CXCR4, but to confirm this further
work will be required, including viral infectivity assays
and specific blocking of infectivity with SDF-1 or mono-
clonal antibodies to CXCR4.
The expression of functional chemokine receptors on
immature CNS-like (hNT) neurons in vitro and the com-
petitive displacement of CXCR4 ligand binding by HIV-1
(strain IIIB) envelope glycoprotein gp120 raise the possi-
bility of neuronal chemokine receptor involvement in
HIV-1-induced neuronal cell dysfunction. It has been
shown that gp120 is toxic to primary embryonic human
and non-human neurons in vitro and in vivo through both
direct binding and indirect interactions with glial cells
[34–36]. The toxic effects are probably mediated by
NMDA receptors, which could be activated by the release
of glutamate by direct or indirect interactions of gp120
with a number of intracellular metabolites [37,38]. 
Our study suggests that direct interactions occur between
neuronal chemokine receptors and soluble monomeric
gp120 (or virus-associated envelope). It is possible that
neurons exposed to HIV could display altered cellular
functions or responses to glia. One recent study demon-
strated trimolecular co-precipitation of CXCR4, CD4 and
gp120 from transfected murine fibroblasts treated with
soluble monomeric gp120 [39]. These authors postulated
that a direct interaction between gp120, CD4 and CXCR4
on the cell surface is necessary for subsequent viral entry.
Our data suggests that gp120 and CXCR4 interact directly
on hNT cells in the absence of CD4. Although it is clear
that hNT cells can be infected by the IIIB strain of HIV-1
[21], it is not yet clear whether viral infectivity occurs by
interaction with CXCR4. However, as chemokine receptor
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activation by chemokines induces chemotactic responses
as well as Ca2+ influxes in myeloid cells [40], similar
effects might be expected in immature neurons. Interest-
ingly, Ca2+ influxes and migration are also observed in
embryonic neurons in response to various extracellular
stimuli, including exposure to the HIV-1 transactivator
protein, Tat [41]. Our observation of chemokine-induced
hNT neuronal migration is consistent with the idea that
human embryonic neuronal cells use chemokine receptors
for chemotaxis, which has not previously been described.
Whether such neuronal chemotactic responses occur in
the developing human brain is unknown, and whether
gp120 expressed in vivo within the developing brain could
interfere with neuronal migration is entirely speculative,
as abnormalities of neuronal migration in HIV-1-infected
fetuses have, to our knowledge, not been described.
Nonetheless, the expression of functional chemokine
receptors on hNT neurons and interference with ligand
binding by gp120 suggest the possibility of secondary
responses to chemokines in neurons and modulation of
such responses by gp120 in vivo. 
Conclusions
Here, we demonstrate that hNT cells express the
chemokine receptors CXCR2, CXCR4, CCR1 and CCR5.
We also show that these receptors are biologically active
and respond physiologically to their ligands. Finally, we
show that the gp120 envelope protein from a T-cell-tropic
virus can inhibit SDF-1 binding to the chemokine receptor
CXCR4 in a CD4-independent manner. As hNT cells are
characteristic of human neurons in the CNS and can be
readily obtained in large numbers by cell culture, they rep-
resent an ideal system for the further examination of the
biological functions of chemokine receptors in the CNS. 
Materials and methods
Materials
SDF-1 was generated by peptide synthesis, purified by high-perfor-
mance liquid chromatography and radiolabeled by the IODO-Bead
method (Pierce Rockford, Illinois) according to the manufacturer’s pro-
tocol. The labeled SDF-1 was purified by gel filtration and the initial
specific activity was 320–426 Ci mmol–1. IIIB gp120 was from ICN
Pharmaceuticals (Costa Mesa, California). IIIB gp120 was radiolabeled
and purified using the method described for SDF-1, and had a specific
activity of 210 Ci mmol–1. 125I-labeled IL-8 and MIP-1b (specific activity
2200 Ci mmol–1) were from NEN. Unlabeled MIP-1a, MIP-1b, MCP-1,
PF-4 and RANTES were from Peprotech (Rocky Hill, New Jersey); IL-8
and MGSA were purified as previously described [42,43]. BRU gp120
was from Biosource (Camarillo, California). Herpes simplex virus type 1
glycoprotein D was isolated as described [44], as was a monoclonal
antibody to galactosylceramide (GalCer) [45]. The CXCR2 antibody
was from Santa Cruz Biotechnology (Santa Cruz, California). The
CXCR4 monoclonal antibody 12G5 was from James Hoxie [33]. The
Fy6 monoclonal antibody to the Duffy blood group antigen (DARC)
was isolated as described [46]. Polyclonal antisera to CCR1 and
CCR5 were raised in New Zealand white rabbits by subcutaneous and
intramuscular injection with the amino-terminal domains of either CCR1
conjugated to KLH or CCR5 conjugated to GST. Following primary
immunization and six challenges with peptide, CCR1 antiserum from
several pooled bleeds was collected and purified over a Pharmacia
5 ml protein-A sepharose Hi-Trap column (Upsala, Sweden). Following
initial immunization with CCR5-conjugated peptide and three chal-
lenges with the antigen, aliquots of anti-CCR5 serum were absorbed
with glutathione S-transferase (GST)–sepharose to remove antibodies
to the GST moiety of the fusion protein. The absorbed antiserum was
used to probe western blots containing GST, CCR5–GST, and the
CCR5 peptide released from the fusion protein by thrombin cleavage.
Purified antibody was analyzed for binding to human kidney 293 cells
transfected with CCR1 and CCR5 by indirect immunofluorescence fol-
lowed by a FACScan. The CD4 antibody, MT310, was from DAKO
(Carpinteria, California). 
Cell culture
Human fetal brain (E17 to E22 weeks) was obtained from Advanced
Bioscience Resources (Alameda, California). Hippocampal regions
were removed under sterile conditions within 2–4 h after fetal demise.
The tissue was placed in 20 ml of Isocoves modified Dulbecco’s
medium (IMDM) and disaggregated by repeated pipetting and then fil-
tration through a metal mesh. Cells were pelleted by centrifugation and
grown in IMDM with 10 % fetal bovine serum (FBS), 2 mM L-glutamine
and 0.5 mg ml–1 gentamicin. Cells were plated at 1 × 106 cells ml–1 in
eight-well plastic chamber slides and grown for 1–2 weeks at 37 °C in
a 5 % CO2 incubator. Media was replaced every 2 days and the sus-
pension of microglia removed. Prior to fixation, the media and cell sus-
pension were removed, with the majority of the remaining cells being
neurons and astrocytes. NTera 2 cells derived from a human embryonic
carcinoma cell line (Ntera 2, clone D1) were obtained from Stratagene
(La Jolla, California) or kindly provided by V.M. Lee (University of Penn-
sylvania). Cells were passaged weekly and maintained in Dulbecco’s
modified Eagles medium (DMEM) with high glucose (4 mM) supple-
mented with heat-inactivated 10 % FBS, 2mM L-glutamine and peni-
cillin/streptomycin. To induce neuronal differentiation, cells were
trypsinized and plated at 2 × 107 cells per 225 cm2 flask in media with
10 mM retinoic acid (RA) for 5 weeks, with fresh media changes twice
weekly. The cells were then replated at 1 × 107 cells in either a
225 cm2 flask or a 100 mm diameter culture dish, in media containing
the mitotic inhibitors 1-b-D-arabinofuranosylcytosine (1 mM), fluo-
rodeoxyuridine (10 mM) and uridine (10 mM) to inhibit non-neuronal
cell division. After two weeks, neuronal cells (hNT) were separated
from precursor cells by differential trypsinization. This was achieved by
mild trypsin treatment for 30 sec followed by gentle knocking to
remove hNT cells from the flask. hNT cells were plated at 5 × 106 cells
per 75 cm2 flask and maintained for up to 1 week in a 50:50 (v/v)
mixture of fresh media plus spent cell culture media (0.22 mm filtered)
from the mitotic inhibitor treatment. In addition, some cells were plated
onto Matrigel (Collaborative Research) as described [16,17]. Some
cells were plated into four- or eight-well plastic chamber slides for
immunohistochemical analysis. hNT cells were shown to be neuronal-
like based upon expression of neurofilament and microtubule-associ-
ated protein antigen by indirect immunofluorescence labeling. Human
kidney embryonic 293 cells and CHO cells were cultured according to
ATCC recommendations.
Indirect antibody labeling FACS method
Human kidney 293 cells or CHO cells were transfected with the plas-
mids that encode specific chemokine receptors (CCR1, CCR5,
CXCR2 or CXCR4) producing stable cell lines. CCR1 or CCR5 poly-
clonal antisera was incubated with cells expressing the corresponding
receptors (sera and cells were diluted 1:500 in Dulbecco’s phosphate-
buffered saline (DPBS) with 0.5 % BSA but without Ca2+ and Mg2+).
Cells were placed on ice for 30–60 min. After the cells were pelleted,
the supernatant was removed and the cells placed back in DPBS and
washed twice. Cells were then incubated with FITC conjugated goat
anti-rabbit antibody (diluted 1:5000 in DPBS) on ice in the dark for 30
min. Cells were pelleted and washed as above. Controls for indirect
labeling contained no primary antibody, pre-immune serum with sec-
ondary antibody, both antibodies but with non-transfected cells, or both
antibodies but with the addition of an amino-terminal peptide.
Immunohistochemistry 
Cultured cells were grown on either four- or eight-well, plastic (Ther-
manox™) chamber slides. Live cells were rinsed in phosphate-buffered
saline (PBS) and then fixed in situ with 4 % paraformaldehyde, 3 %
sucrose in PBS, pH 7.3. After 1 h the fixative was removed and the
cells were carefully washed twice in PBS and then stored in PBS at
4 °C until the time of staining. Before staining, the cells were blocked
for 30 min in PBS containing 0.005 % Triton X-100 and 10 % serum
from either goat or donkey (depending on the species of the secondary
antibody). The blocking solution was removed and the primary antibod-
ies (diluted in the same buffer used for blocking) were added without a
rinse step. After a 1 h incubation at room temperature, the primary anti-
bodies were removed, the tissues were rinsed in PBS, and the staining
was completed using a peroxidase-linked (BioGenex) avidin–biotin
staining kit appropriate to the species of the primary antibody. The
reaction was visualized with diaminobenzidine as chromogen and the
cells were lightly counter-stained with hematoxylin to increase nuclear
definition. Cells grown on plastic were air-dried and then mounted with
glass coverslips using Gelmount™ (Sigma). Cells were viewed on a
Zeiss Axioskop and photographed with an attached Fuji HC-2000,
three-chip CCD digital camera. Images were first edited in Adobe Pho-
toshop 3.0 to enhance contrast and white balance and then printed on
a Fuji Pictrography 3000 digital printer.
Chemokine binding studies
hNT cells in 16-well, plastic (Thermanox™) chamber slides were incu-
bated in PBS with radiolabeled chemokines (500 pM) in the presence
and absence of increasing concentrations of unlabeled chemokines at
room temperature for 30 min. In addition, HIV-1 IIIB gp120 (ICN) was
used to displace 125I-labeled SDF-1. The incubation was terminated by
gentle aspiration of the supernatant. The cells were washed once in
PBS and solubilized by the addition of 100 ml of 25 % SDS, and trans-
ferred to vials for counting in a gamma counter. Nonspecific binding
was determined in the presence of 1 mM unlabeled chemokines. Each
chemokine or gp120 protein concentration was tested in duplicate.
The binding data were curve-fitted with the computer program IGOR
(Wavemetrics) to determine the affinity (KD), number of sites and
amount of non-specific binding. 
Chemotaxis
Differentiated and non-differentiated NTera 2 cell migration was exam-
ined using a 48-well microchemotaxis assay as previously described
[47]. Briefly, various concentrations of chemokine were placed in the
lower wells of a 48-well microchemotaxis chamber. Human NTera 2
and hNT cells (2–5 × 106 cells ml–1) were then placed in the upper
compartment of the chamber. The upper and lower wells of the
chamber were separated by a 5 mm polycarbonate filter coated with
laminin (Sigma, St. Louis, Missouri), which seems to be optimal for
human neural cell migration in vitro. The chambers were incubated for
4 h at 37 °C (a time period over which chemokine equilibrium between
the upper and lower chambers is optimally achieved) after which the
filters were scraped, washed, fixed with methanol and stained with Diff-
Quik. Cell migration was measured by counting the number of cells
attached to the lower surface of the filter in five high-power fields. Each
concentration of chemokine was tested in either triplicate or sets of six
wells. The results were expressed as the number of migrating cells per
five high-power fields (± SE). 
Acknowledgements
The first two authors contributed equally to this study. We thank Sara Bian-
calana and Stewart Thompson for the chemical synthesis of SDF-1, Susan
Harvey and Hai-Lung Guo for flow cytometry and Jian-Guo Du for preparing
the CCR5 amino-terminal fusion protein. We also thank Myrna Faulds for
help in the preparation of figures for this paper, and Ronald Collman and
Jean Merrill for helpful input into the preparation of this manuscript. 
References 
1. Schall T: The chemokines. In The Cytokine Handbook. Edited by
Thompson A. San Diego: Academic Press; 1994:419–460.
2. Horuk R: Molecular properties of the chemokine receptor family.
Trends Pharmacol Sci 1994, 15:159–165.
3. Mackay CR: Chemokine receptors and T cell chemotaxis. J Exp
Med 1996, 184:799–802.
4. Cocchi F, DeVico AL, Garzino-Demo A, Arya SK, Gallo RC, Lusso P:
Identification of RANTES, MIP-1a, and MIP-1b as the major HIV-
suppressive factors produced by CD8+ T cells. Science 1995,
270:1811–1815.
5. Oberlin E, Amara A, Bachelerie F, Bessia C, Virelizier JL, Arenzana-
Seisdedos F, et al.: The CXC chemokine SDF-1 is the ligand for
LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1.
Nature 1996, 382:833–835.
6. Bleul CC, Farzan M, Choe H, Parolin C, Clark-Lewis I, Sodroski J, et
al.: The lymphocyte chemoattractant SDF-1 is a ligand for
LESTR/fusin and blocks HIV-1 entry. Nature 1996, 382:829–833.
7. Feng Y, Broder CC, Kennedy PE, Berger EA: HIV-1 entry cofactor:
Functional cDNA cloning of a seven-transmembrane, G-protein-
coupled receptor. Science 1996, 272:872–877.
8. Dragic T, Litwin V, Allaway GP, Martin SR, Huang YX, Nagashima KA,
et al.: HIV-1 entry into CD4+ cells is mediated by the chemokine
receptor CC-CKR-5. Nature 1996, 381:667–673.
9. Deng HK, Liu R, Ellmeier W, Choe S, Unutmaz D, Burkhart M, et al.:
Identification of a major co-receptor for primary isolates of HIV-1.
Nature 1996, 381:661–666.
10. Doranz BJ, Rucker J, Yi YJ, Smyth RJ, Samson M, Peiper SC, et al.: A
dual-tropic primary HIV-1 isolate that uses fusin and the b-
chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion
cofactors. Cell 1996, 85:1149–1158.
11. Choe H, Farzan M, Sun Y, Sullivan N, Rollins B, Ponath PD, et al.: The
b-chemokine receptors CCR3 and CCR5 facilitate infection by
primary HIV-1 isolates. Cell 1996, 85:1135–1148.
12. Janssen RS, Cornblath DR, Epstein LG, Foa RP, McArthur JC, Price
RW: Nomenclature and research case definitions for neurologic
manifestations of human immunodeficiency virus-type 1 (HIV-1)
infection. Neurology 1991, 41:778–785.
13. Epstein LG, Sharer LR, Oleske JM, Connor EM, Goudsmit J, Bagdon
L, et al.: Neurologic manifestations of human immunodeficiency
virus infection in children. Pediatrics 1986, 78:678–687.
14. Belman AL: HIV-1-associated central nervous system disease in
infants and children. In HIV, AIDS, and the Brain. Edited by Price
RW and Perry SW. New York: Raven Press; 1994:289–310.
15. Horuk R, Martin AW, Wang ZX, Scweitzer L, Gerassimides A, Lu ZH,
et al.: Hierarchical expression of chemokine receptors by subsets
of neurons in the normal central nervous system and
neurodegenerative disorders. J Immunol 1997, in press. 
16. Andrews PW: Retinoic acid induces neuronal differentiation of a
cloned human embryonal carcinoma cell line in vitro. Dev Biol
1984, 103:285–293.
17. Pleasure SJ, Page C, Lee VM-Y: Pure, postmitotic, polarized human
neurons derived from NTera 2 cells provide a system for
expressing exogenous proteins in terminally differentiated
neurons. J Neurosci 1992, 12:1802–1815.
18. Younkin DP, Tang CM, Hardy M, Reddy UR, Shi QY, Pleasure SJ, et
al.: Inducible expression of neuronal glutamate receptor channels
in the NT2 human cell line. Proc Natl Acad Sci USA 1993,
90:2174–2178.
19. Llanes C, Collman RG, Hrin R, Kolson DL: Acetylcholinesterase
expression in NTera 2 human neuronal cells: a model for
developmental expression in the nervous system. J Neurosci Res
1995, 42:791–802.
20. Pleasure SJ, Lee VM: NTera 2 cells: a human cell line which
displays characteristics expected of a human committed neuronal
progenitor cell. J Neurosci Res 1993, 35:585–602.
21. Hirka G, Prakash K, Kawashima H, Plotkin SA, Andrews PW, Gonczol
E: Differentiation of human embryonal carcinoma cells induces
human immunodeficiency virus permissiveness which is
stimulated by human cytomegalovirus coinfection. J Virol 1991,
65:2732–2735.
22. Lee J, Horuk R, Rice GC, Bennett GL, Camerato T, Wood WI:
Characterization of two high affinity human interleukin-8
receptors. J Biol Chem 1992, 267:16283–16287.
23. Samson M, Labbe O, Mollereau C, Vassart G, Parmentier M:
Molecular cloning and functional expression of a new human
CC-chemokine receptor gene. Biochemistry 1996,
35:3362–3367.
24. Harouse JH, Bhat S, Spitalnik SL, Laughlin M, Stefano K, Silberberg
DH, et al.: Inhibition of entry of HIV-1 in neural cell lines by
antibodies against galactosyl ceramide. Science 1991,
253:320–323.
120 Current Biology, Vol 7 No 2
25. Federsppiel B, Melhado IG, Duncan AM, Delaney A, Schappert K,
Clark-Lewis I, et al.: Molecular cloning of the cDNA and
chromosomal localization of the gene for a putative seven-
transmembrane segment (7-TMS) receptor isolated from human
spleen. Genomics 1993, 16:707–712.
26. Loetscher M, Geiser T, O'Reilly T, Zwahlen R, Baggiolini M, Moser B:
Cloning of a human seven-transmembrane domain receptor,
LESTR, that is highly expressed in leukocytes. J Biol Chem 1994,
269:232–237.
27. Bleul CC, Fuhlbrigge RC, Casasnovas JM, Aiuti A, Springer TA: A
highly efficacious lymphocyte chemoattractant, stromal cell-
derived factor 1 (SDF-1). J Exp Med 1996, 184:1101–1109.
28. Ransohoff RM, Hamilton TA, Tani M, Stoler MH, Shick HE, Major JA,
et al.: Astrocyte expression of mRNA encoding cytokines IP-10
and JE/MCP-1 in experimental autoimmune encephalomyelitis.
FASEB J 1993, 7:592–600.
29. Godiska R, Chantry D, Dietsch GN, Gray PW: Chemokine
expression in murine experimental allergic encephalomyelitis. J
Neuroimmunol 1995, 58:167–176.
30. Karpus WJ, Lukacs NW, McRae BL, Strieter RM, Kunkel SL, Miller
SD: An important role for the chemokine macrophage
inflammatory protein-1a in the pathogenesis of the T cell-
mediated autoimmune disease, experimental autoimmune
encephalomyelitis. J Immunol 1995, 155:5003–5010.
31. Rothwell NJ, Hardwick AJ, Lindley I: Central actions of interleukin-8
in the rat are independent of prostaglandins. Horm Metab Res
1990, 22:595–596.
32. Araujo DM, Cotman CW: Trophic effects of interleukin-4, -7 and -8
on hippocampal neuronal cultures: potential involvement of glial-
derived factors. Brain Res 1993, 600:49–55.
33. Endres MJ, Clapham PR, Marsh M, Ahuja M, Turner JD, McKnight A,
et al.: CD4-independent infection by HIV-2 is mediated by
Fusin/CXCR4. Cell 1996, 87:745–756.
34. Toggas SM, Masliah E, Rockenstein EM, Rall GF, Abraham CR,
Mucke L: Central nervous system damage produced by
expression of the HIV-1 coat protein gp120 in transgenic mice.
Nature 1994, 367:188–193.
35. Giulian D, Wendt E, Vaca K, Noonan CA: The envelope glycoprotein
of human immunodeficiency virus type 1 stimulates release of
neurotoxins from monocytes. Proc Natl Acad Sci USA 1993,
90:2769–2773.
36. Brenneman DE, Westbrook GL, Fitzgerald SP, Ennist DL, Elkins KL,
Ruff MR, et al.: Neuronal cell killing by the envelope protein of HIV
and its prevention by vasoactive intestinal peptide. Nature 1988,
335:639–642.
37. Tardieu M, Héry C, Peudenier S, Boespflug O, Montagnier L: Human
immunodeficiency virus type 1-infected monocytic cells can
destroy human neural cells after cell-to-cell adhesion. Ann Neurol
1992, 32:11–17.
38. Genis P, Jett M, Bernton EW, Boyle T, Gelbard HA, Dzenko K, et al.:
Cytokines and arachidonic metabolites produced during human
immunodeficiency virus (HIV)-infected macrophage-astroglia
interactions: Implications for the neuropathogenesis of HIV
disease. J Exp Med 1992, 176:1703–1718.
39. Lapham CK, Ouyang J, Chandrasekhar B, Nguyen NY, Dimitrov DS,
Golding H: Evidence for cell-surface association between fusin
and the CD4–gp120 complex in human cell lines. Science 1996,
274:602–605.
40. Baggiolini M: Chemotactic and inflammatory cytokines: CXC and
CC proteins. Adv Exp Med Biol 1994, 351:1–11.
41. Sabatier JM, Vives E, Mabrouk K, Benjouad A, Rochat H, Duval A, et
al.: Evidence for neurotoxic activity of tat from HIV-1. J Virol 1991,
65:961–967.
42. Hébert CA, Luscinskas FW, Kiely J-M, Luis EA, Darbonne WC,
Bennett GL, et al.: Endothelial and leukocyte forms of IL-8:
conversion by thrombin and interaction with neutrophils.
J Immunol 1990, 145:3033–3040.
43. Horuk R, Yansura DG, Reilly D, Spencer S, Bourell J, Henzel W, et al.:
Purification, receptor binding analysis, and biological
characterization of human melanoma growth stimulating activity
(MGSA). Evidence for a novel MGSA receptor. J Biol Chem 1993,
268:541–546.
44. Nicola AV, Willis SH, Naidoo NN, Eisenberg RJ, Cohen GH:
Structure–function analysis of soluble forms of herpes simplex
virus glycoprotein D. J Virol 1996, 70:3815–3822.
45. Long D, Berson JF, Cook DG, Doms RW: Characterization of
human immunodeficiency virus type 1 gp120 binding to
liposomes containing galactosylceramide. J Virol 1994,
68:5890–5898.
46. Nichols ME, Rubinstein P, Barnwell J, de Cordoba SR, Rubinstein RE:
A new human duffy blood group specificity defined by a murine
monoclonal antibody. J Exp Med 1987, 166:776–785.
47. Taub DD, Key ML, Clark D, Turcovski-Corrales SM: Chemotaxis of T
lymphocytes on extracellular matrix proteins. Analysis of the in
vitro method to quantitate chemotaxis of human T cells.
J Immunol Meth 1995, 184:187–98.
Research Paper  Chemokine receptors in human neurons Hesselgesser et al.    121
